Fig. 1
4 T1 mammary carcinoma tumors induce expansion of splenic myeloid cells. C57Bl/6 mice were inoculated with either 105 B16 (n = 6) or 105 EL4 (n = 7) cells and BALB/c mice were inoculated with 105 4 T1 cells (n = 7) s.c. Naïve C57Bl/6 or BALB/c mice (n = 3) were included as controls for each tumor type. Spleens and tumors were collected 7 days post-inoculation and analyzed by flow cytometry. a, Frequency of splenic CD11b+ myeloid cells gated from total viable cells. b, Number of splenic CD11b+, Ly6Chi, Ly6Ghi and SiglecF+ cells in naïve and 4 T1 tumor-bearing mice. c, Gating strategy for the identification of SSChi SiglecF+, Ly6Chi and Ly6Ghi cells within the CD11b+ CD45.2+ cell population in a 4 T1 tumor. d, Pie chart showing the composition of the CD11b+ cell population in a 4 T1 tumor. Representative results of at least two independent experiments are shown for all experimental settings. *P < 0.05, Mann–Whitney U-test